title: A case of acne fulminans in a patient with ulcerative colitis successfully treated with prednisolone and diaminodiphenylsulfone: a literature review of acne fulminans, rosacea fulminans and neutrophilic dermatoses occurring in the setting of inflammatory bowel disease.
abstract: A 19-year-old Japanese man had been treated for ulcerative colitis for 2 years. He was admitted to our hospital with nodulocystic inflammatory papules and pustules on his face and chest, high-grade fever, arthralgia and general malaise. A biopsy specimen from a pustule showed prominent infiltration of neutrophils in the epidermis and dermis, particularly around hair follicles. We made a diagnosis of acne fulminans. The systemic administration of prednisolone at 30 mg daily for 1 week immediately improved his skin lesions and other symptoms; however, during tapering of prednisolone at 20 mg daily, skin lesions flared up. The addition of oral diaminodiphenylsulfone improved the skin lesions. Although there have been a few reports of acne fulminans associated with Crohn's disease, this is the first case report of acne fulminans in a patient with ulcerative colitis. It is noteworthy that the addition of diaminodiphenylsulfone was effective for treating the relapse of acne fulminans in this case.
authors.affiliation: Department of Dermatology, Shiga University of Medical Science, Otsu, Shiga, Japan. mako0218@belle.shiga-med.ac.jp
authors.forename: Makiko
authors.initials: M
authors.lastname: Wakabayashi
authors.forename: Noriki
authors.initials: N
authors.lastname: Fujimoto
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Uenishi
authors.forename: Kiichiro
authors.initials: K
authors.lastname: Danno
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Tanaka
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy* / Q000473:pathology; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001706:Biopsy; D002511:Cephalosporins / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000150:complications / Q000188:drug therapy*; D003622:Dapsone / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004890:Erythema / Q000188:drug therapy / Q000473:pathology; D024841:Fluoroquinolones / Q000627:therapeutic use; D006016:Glycolates / Q000627:therapeutic use; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000627:therapeutic use; D009504:Neutrophils / Q000187:drug effects / Q000473:pathology; D011239:Prednisolone / Q000627:therapeutic use*; D011807:Quinolizines / Q000627:therapeutic use; D012393:Rosacea / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome; D055815:Young Adult; D000097586:Cefozopran
chemical_list: D000893:Anti-Inflammatory Agents; D002511:Cephalosporins; D003622:Dapsone; D003879:Dermatologic Agents; D024841:Fluoroquinolones; D006016:Glycolates; D019804:Mesalamine; D011239:Prednisolone; D011807:Quinolizines; D000097586:Cefozopran; C031149:glycolic acid; C062127:nadifloxacin